EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nobiletin, as a Novel PDE4B Inhibitor, Alleviates Asthma Symptoms by Activating the cAMP-PKA-CREB Signaling Pathway

Yan Zhang, Yaping Yang, Huicong Liang, Yuerun Liang, Guixin Xiong, Fang Lu, Kan Yang, Qi Zou, Xiaomin Zhang, Guanhua Du, Ximing Xu iD, Jiejie Hao

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251910406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yan Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China. Hauptthemen laut MEDLINE: Flavones, Asthma, Cyclic Nucleotide Phosphodiesterases, Type 4, Signal Transduction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special Funds of Shandong Province for Qingdao National Laboratory of Marine Science and Technology and Key research, Development program of Shandong Province, Special Funds of Shandong Province for Qingdao National Laboratory of Marine Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a chronic airway inflammation that is considered a serious public health concern worldwide. Nobiletin (5,6,7,8,3′,4′-hexamethyl flavonoid), an important compound isolated from several traditional Chinese medicines, especially Citri Reticulatae Pericarpium, is widely used for a number of indications, including cancer, allergic diseases, and chronic inflammation. However, the mechanism by which nobiletin exerts its anti-asthmatic effect remains unclear. In this research, we comprehensively demonstrated the anti-asthmatic effects of nobiletin in an animal model of asthma. It was found that nobiletin significantly reduced the levels of inflammatory cells and cytokines in mice and alleviated airway hyperresponsiveness. To explore the target of nobiletin, we identified PDE4B as the target of nobiletin through pharmacophore modeling, molecular docking, molecular dynamics simulation, SPR, and enzyme activity assays. Subsequently, it was found that nobiletin could activate the cAMP-PKA-CREB signaling pathway downstream of PDE4B in mouse lung tissues. Additionally, we studied the anti-inflammatory and anti-airway remodeling effects of nobiletin in LPS-induced RAW264.7 cells and TGF-β1-induced ASM cells, confirming the activation of the cAMP-PKA-CREB signaling pathway by nobiletin. Further validation in PDE4B-deficient RAW264.7 cells confirmed that the increase in cAMP levels induced by nobiletin depended on the inhibition of PDE4B. In conclusion, nobiletin exerts anti-asthmatic activity by targeting PDE4B and activating the cAMP-PKA-CREB signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlavonesAsthmaCyclic Nucleotide Phosphodiesterases, Type 4Signal TransductionCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinCyclic AMPAnimalsMicePhosphodiesterase 4 InhibitorsMolecular Docking SimulationDisease Models, AnimalMice, Inbred BALB CRAW 264.7 CellsMale

Stichwörter der Autor:innen

asthmacAMP-PKA-CREB signaling pathwaynobiletinreverse dockingtraditional chinese medicine

Substanzen

nobiletinFlavonesCyclic Nucleotide Phosphodiesterases, Type 4Cyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinCyclic AMPPhosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
  • Marine Biomedical Research Institute of Qingdao, Qingdao 266071, China.
  • Qingdao Marine Science and Technology Center, Qingdao 266237, China.

ORCID-Profile: Ximing Xu

Förderung

  • Special Funds of Shandong Province for Qingdao National Laboratory of Marine Science and Technology and Key research
  • Development program of Shandong Province
  • Special Funds of Shandong Province for Qingdao National Laboratory of Marine Science and Technology

Zitieren

APA

Zhang, Y., Yang, Y., Liang, H., Liang, Y., Xiong, G., Lu, F., Yang, K., Zou, Q., Zhang, X., Du, G., Xu, X., & Hao, J. (2024). Nobiletin, as a Novel PDE4B Inhibitor, Alleviates Asthma Symptoms by Activating the cAMP-PKA-CREB Signaling Pathway. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910406

Vancouver

Zhang Y, Yang Y, Liang H, Liang Y, Xiong G, Lu F, et al. Nobiletin, as a Novel PDE4B Inhibitor, Alleviates Asthma Symptoms by Activating the cAMP-PKA-CREB Signaling Pathway. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910406

BibTeX
@article{Zhang2024,
  author = {Zhang, Yan and Yang, Yaping and Liang, Huicong and Liang, Yuerun and Xiong, Guixin and Lu, Fang and Yang, Kan and Zou, Qi and Zhang, Xiaomin and Du, Guanhua and Xu, Ximing and Hao, Jiejie},
  title = {Nobiletin, as a Novel PDE4B Inhibitor, Alleviates Asthma Symptoms by Activating the cAMP-PKA-CREB Signaling Pathway},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251910406}
}
Kostenlos starten →